New research published in The Journal of Immunology reveals how high blood sugar and type 1 diabetes may protect against certain cancers including melanoma, breast and colon cancer. The findings could inform development of new cancer immunotherapy treatments by explaining the previously mysterious association between T1D and decreased cancer risk.
Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.
Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.
Amylyx Pharmaceuticals' experimental drug avexitide met its primary endpoint in a Phase 3 trial for post-bariatric hypoglycemia, showing a 55% reduction in serious low blood sugar events compared to placebo in patients who experienced dangerously low blood sugar following weight-loss surgery.
A major clinical trial found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin, offering evidence for expanded use of the technology beyond type 1 diabetes.
New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.